Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Longbin Liu

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Journal of Medicinal Chemistry|June 17, 2008
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)Longbin Liu, Aaron Siegmund, Ning Xi, et al.
Bioorganic & Medicinal Chemistry Letters|July 27, 2012
Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffoldRyan P Wurz, Longbin Liu, Kevin Yang, et al.
Journal of Medicinal Chemistry|March 12, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N'-arylpiperazine seriesNobuko Nishimura, Mark H Norman, Longbin Liu, et al.
Journal of Medicinal Chemistry|May 27, 2011
Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivativesNobuko Nishimura, Aaron Siegmund, Longbin Liu, et al.
Journal of Medicinal Chemistry|September 4, 2008
Design, synthesis, and biological evaluation of potent c-Met inhibitorsNoel D D'Angelo, Steven F Bellon, Shon K Booker, et al.
Science Translational Medicine|February 2, 2022
Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's diseaseDaniele Bertoglio, Jonathan Bard, Manuela Hessmann, et al.
Scientific Reports|September 10, 2021
Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidatesFrank Herrmann, Manuela Hessmann, Sabine Schaertl, et al.
Journal of Medicinal Chemistry|February 22, 2011
Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitorsNoel D D'Angelo, Tae-Seong Kim, Kristin Andrews, et al.
Journal of Medicinal Chemistry|January 11, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profilesDavid J St Jean, Kate S Ashton, Michael D Bartberger, et al.
Frontiers in Pharmacology|March 7, 2019
Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate AirwaysKent Miner, Katja Labitzke, Benxian Liu, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Journal of Medicinal Chemistry|June 17, 2008
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)Longbin Liu, Aaron Siegmund, Ning Xi, et al.
Bioorganic & Medicinal Chemistry Letters|July 27, 2012
Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffoldRyan P Wurz, Longbin Liu, Kevin Yang, et al.
Journal of Medicinal Chemistry|March 12, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N'-arylpiperazine seriesNobuko Nishimura, Mark H Norman, Longbin Liu, et al.
Journal of Medicinal Chemistry|May 27, 2011
Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivativesNobuko Nishimura, Aaron Siegmund, Longbin Liu, et al.
Journal of Medicinal Chemistry|September 4, 2008
Design, synthesis, and biological evaluation of potent c-Met inhibitorsNoel D D'Angelo, Steven F Bellon, Shon K Booker, et al.
Science Translational Medicine|February 2, 2022
Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's diseaseDaniele Bertoglio, Jonathan Bard, Manuela Hessmann, et al.
Scientific Reports|September 10, 2021
Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidatesFrank Herrmann, Manuela Hessmann, Sabine Schaertl, et al.
Journal of Medicinal Chemistry|February 22, 2011
Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitorsNoel D D'Angelo, Tae-Seong Kim, Kristin Andrews, et al.
Journal of Medicinal Chemistry|January 11, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profilesDavid J St Jean, Kate S Ashton, Michael D Bartberger, et al.
Frontiers in Pharmacology|March 7, 2019
Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate AirwaysKent Miner, Katja Labitzke, Benxian Liu, et al.
Pageof 6